A5079855663- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Meta-analysis and systematic reviews
- Colorectal Cancer Treatments and Studies
- Effects of Radiation Exposure
- Cancer Immunotherapy and Biomarkers
- Orthopedic Infections and Treatments
- Sepsis Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Machine Learning in Healthcare
- Lanthanide and Transition Metal Complexes
- Microscopic Colitis
- Brain Metastases and Treatment
- Cardiac tumors and thrombi
- COVID-19 and healthcare impacts
Cancer Research UK Clinical Trials Unit
2021-2025
University of Birmingham
2020-2025
11500 Background: In 2010, different chemotherapy regimens were standard in Europe and the USA for newly diagnosed ES. absence of novel agents to investigate, comparison these two strategies was considered worthwhile. Methods: Newly localised or metastatic ES patients aged 5-50 eligible. Patients randomized receive either European regimen (Arm A) VIDE (vincristine [V], ifosfamide [I], doxorubicin [D] etoposide [E]) induction VAI VAC (V, actinomycin D I cyclophosphamide [C]) consolidation B)...
11502 Background: Five-year survival of RR-ES is about 15%. Several chemotherapy regimens are used, but without robust evidence. rEECur, the first randomised controlled trial in this setting, defining a standard care, balancing efficacy and toxicity. Methods: Patients aged 4 to 50 with fit receive were between topotecan & cyclophosphamide (TC), irinotecan temolozomide (IT), gemcitabine docetaxel (GD) or high-dose ifosfamide (IFOS). Primary outcome measure was objective response (OR)...
LBA2 Background: 5-year survival of RR-ES is about 15%. rEECur, the first randomized controlled trial in this setting, defining standard care, balancing efficacy and toxicity. Methods: Patients aged 4-50 with were randomly assigned to topotecan cyclophosphamide (TC), irinotecan temolozomide (IT), gemcitabine docetaxel (GD), or high-dose ifosfamide (IFOS). Primary outcome was event-free (EFS) for phase III comparison. Secondary outcomes included overall (OS), toxicity, quality life (QoL). A...
Children with cancer are not at increased risk of severe SARS-CoV-2 infection; however, adults haematological malignancies have infections compared non-haematological malignancies.
10006 Background: rEECur, the first randomised controlled trial (RCT) in RR-ES, has previously defined high dose ifosfamide (IFOS) as most effective regimen this setting compared to gemcitabine-docetaxel, irinotecan-temozolomide and topotecan-cyclophosphamide. Platinum drugs show activity RR-ES are frequently given with etoposide setting. Methods: Patients aged at least 2 years were 3-week cycles of either IFOS 15 g/m by continuous intravenous (IV) infusion over 5 days or IV carboplatin 400...
Colitis was the third most common immune-related adverse effect in melanoma patients treated with immune-checkpoint inhibitor (ICI). With limitation of real-world data UK population, this study conducted a hospital where fresh colitis guidance introduced to evaluate overall grading (OG) assess severity and guide treatment.
Abstract BACKGROUND Current European standard-of-care for localised intracranial germinoma is multi-agent chemotherapy (carboPEI: carboplatin/etoposide/ifosfamide) followed by definitive radiotherapy, with excellent survival. MonoGerm a de-escalation, non-inferiority trial aiming to reduce toxicity. Twelve-week carboplatin (PMID:8039122) AUC10 or vinblastine (PMIDs:32642701/34520101) induction will be evaluated test if as effective carboPEI from SIOP-CNS-GCT-II. A novel design was required...
Abstract BACKGROUND Current European standard-of-care for localised intracranial germinoma is multi-agent chemotherapy (carboPEI: carboplatin/etoposide/ifosfamide) followed by definitive radiotherapy, with excellent survival. MonoGerm a de-escalation, non-inferiority trial aiming to reduce toxicity. Twelve-week carboplatin (PMID:8039122) AUC10 or vinblastine (PMIDs:32642701/34520101) induction will be evaluated test if as effective carboPEI from SIOP-CNS-GCT-II. A novel design was required...
Ewing sarcoma is a rare paediatric cancer. Currently, there no way of accurately predicting these patients' survival at diagnosis. Disease type (ie, localised disease, lung/pleuropulmonary metastases and other metastases) used to guide treatment decisions, with metastatic patients generally having worse outcomes than disease patients. However, not all fit this trend. An accurate prognostic model could be decisions in clinical practice avoid being incorrectly under or overtreated. This study...
Abstract BACKGROUND: Intracranial germinoma is chemosensitive but radiotherapy (RT) needed for cure. In localised disease, three-drug standard-of-care (SOC) inpatient chemotherapy used to reduce RT fields/dose. Concomitant diabetes insipidus common, making delivery challenging. Small studies have demonstrated benefits from single-agent carboplatin or vinblastine in as an alternative SOC. However, this needs prospective evaluation a clinical trial. METHODS: We developed trial, with...